Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.

ABSTRACT:

Background

HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear.

Methods

We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2_low) and 94 HER2-negtive (HER2_neg) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2_neg vs. HER2_low, 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples.<

SUBMITTER: Hu XE 

PROVIDER: S-EPMC10061837 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature